

Marc A Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1213539/publications.pdf>

Version: 2024-02-01

39
papers

951
citations

567281

15
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

1509
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. <i>Molecular Systems Biology</i> , 2017, 13, 955.	7.2	163
2	AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. <i>International Journal of Oncology</i> , 2017, 50, 365-372.	3.3	110
3	Identification of the dynein light chains required for human papillomavirus infection. <i>Cellular Microbiology</i> , 2011, 13, 32-46.	2.1	86
4	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1800564.	6.7	54
5	Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. <i>Cancers</i> , 2019, 11, 1306.	3.7	52
6	Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3529-3540.	7.0	45
7	FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC. <i>Cancers</i> , 2019, 11, 652.	3.7	45
8	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. <i>Lung Cancer</i> , 2021, 153, 150-157.	2.0	45
9	Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 202-222.	4.1	38
10	Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. <i>EBioMedicine</i> , 2020, 62, 103103.	6.1	32
11	The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. <i>Journal of Virology</i> , 2016, 90, 10629-10641.	3.4	28
12	An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e11902.	6.9	28
13	The Transcription Factors TBX2 and TBX3 Interact with Human Papillomavirus 16 (HPV16) L2 and Repress the Long Control Region of HPVs. <i>Journal of Virology</i> , 2013, 87, 4461-4474.	3.4	23
14	The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC). <i>Lung Cancer</i> , 2018, 120, 46-53.	2.0	22
15	Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. <i>Lung Cancer</i> , 2018, 119, 48-55.	2.0	21
16	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. <i>Lung Cancer</i> , 2018, 126, 80-88.	2.0	16
17	Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. <i>Oncotarget</i> , 2016, 7, 71285-71297.	1.8	13
18	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. <i>Cancers</i> , 2020, 12, 3528.	3.7	13

#	ARTICLE	IF	CITATIONS
19	Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. <i>Lung Cancer</i> , 2019, 130, 194-200.	2.0	12
20	Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020, 9, 1755.	4.1	12
21	Profibrotic epithelial TGF- β 1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L356-L367.	2.9	12
22	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. <i>Cancers</i> , 2018, 10, 486.	3.7	11
23	Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2019, 54, 515-526.	3.3	10
24	Impact of Natural or Synthetic Singletons in the Capsid of Human Bocavirus 1 on Particle Infectivity and Immunoreactivity. <i>Journal of Virology</i> , 2020, 94, .	3.4	10
25	A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. <i>Clinical Lung Cancer</i> , 2021, 22, 142-146.	2.6	10
26	DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. <i>Clinical Epigenetics</i> , 2021, 13, 38.	4.1	8
27	Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study. <i>Frontiers in Oncology</i> , 2022, 12, 772076.	2.8	8
28	Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 3707-13.	1.1	6
29	Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
30	Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers. <i>Cancer Research</i> , 2022, 82, 3116-3129.	0.9	4
31	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022, 14, 2479.	3.7	3
32	Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. <i>Genes</i> , 2022, 13, 759.	2.4	2
33	Establishment of a Tissue-Mimicking Surrogate for Pulmonary Lesions to Improve the Development of RFA Instruments and Algorithms. <i>Biomedicines</i> , 2022, 10, 1100.	3.2	2
34	Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. <i>Cancers</i> , 2020, 12, 3834.	3.7	1
35	Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21627-e21627.	1.6	1
36	Longitudinal ctDNA analysis to enable early assessment of prognosis in lung adenocarcinoma in the absence of matched tissue biopsy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12077-12077.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Early assessment of treatment effect in advanced lung adenocarcinoma via longitudinal ctDNA analysis.. Journal of Clinical Oncology, 2018, 36, 12088-12088.	1.6	0
38	Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.. Journal of Clinical Oncology, 2019, 37, e20701-e20701.	1.6	0
39	Blood gene expression changes in metastatic lung cancer under first-line immunotherapy according to clinical response.. Journal of Clinical Oncology, 2022, 40, e21141-e21141.	1.6	0